Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Transaminase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN120718880B reveals high-efficiency transaminase mutant for Cinacalcet intermediate synthesis offering significant cost and supply chain advantages.
Patent CN103014081A details a green enzymatic route for 3-amino-4-(2,4,5-trifluorophenyl)methyl butyrate, offering superior chirality and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN110951706B details a high-activity R-omega-TA mutant for sitagliptin. Offers high ee value >99%, breaking technical monopolies and ensuring supply chain stability.
Novel transaminase mutant enables high-yield sitagliptin intermediate synthesis with superior stereoselectivity and scalable biocatalytic process efficiency for global supply.
Patent CN117701523A reveals solvent-tolerant transaminase for high-purity sitagliptin intermediate manufacturing with significant supply chain cost reduction.
Patent CN113061594A details a robust immobilized transaminase process for sitagliptin intermediates, offering superior stability and simplified solvent systems for cost-effective API manufacturing.
Patent CN117660389A reveals mutant transaminase for chiral amines. Offers high conversion and purity for pharma and agrochemical manufacturing supply chains.
Novel (R)-ω-transaminase mutant enables high-conversion synthesis of Sitagliptin intermediates, offering cost-effective and scalable pharmaceutical manufacturing solutions.
Patent CN111411094B discloses a novel mutant enzyme achieving 95.4% conversion at high substrate concentrations, offering significant cost reduction in API manufacturing.
Patent CN108866021B details a novel transaminase mutant for synthesizing sitagliptin intermediates with >99% ee. Discover cost-effective biocatalytic solutions for API manufacturing.
Patent CN110540975B reveals high-efficiency biocatalytic route for sitagliptin precursors, offering superior stereoselectivity and reduced environmental impact for pharma supply chains.
Patent CN115896060A reveals a novel ω-transaminase mutant for silodosin synthesis, offering >99% ee and scalable biocatalysis for reliable supply chains.
Patent CN106995807A enables high-purity Sitagliptin intermediate synthesis via recombinant transaminase, offering supply chain stability and cost efficiency.
Patent CN108823179A reveals high-efficiency transaminase mutant for R-3-aminobutanol, offering significant cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN121204184A reveals high-purity biocatalytic route. Enhanced scalability and cost efficiency for pharmaceutical manufacturing supply chains.
Patent CN110358804B reveals high-purity enzymatic resolution for dolutegravir synthesis, offering scalable biocatalysis solutions for reliable pharmaceutical intermediate suppliers.
Novel enzymatic synthesis route for HIV integrase inhibitor intermediates. High purity, scalable process offering significant supply chain stability and cost efficiency for pharmaceutical partners.
Novel enzymatic synthesis method for high-purity chiral cis-cyclohexanediamine. Scalable process reduces impurities and ensures supply chain reliability for anticoagulant manufacturing.
Patent CN107586796A reveals enzymatic synthesis for high-purity chiral amines. Offers scalable cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN121495896A reveals enhanced enzyme catalysis for chiral amine synthesis offering significant cost reduction and supply chain reliability for agrochemical manufacturing.